IT1240643B - Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano - Google Patents

Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano

Info

Publication number
IT1240643B
IT1240643B IT20273A IT2027390A IT1240643B IT 1240643 B IT1240643 B IT 1240643B IT 20273 A IT20273 A IT 20273A IT 2027390 A IT2027390 A IT 2027390A IT 1240643 B IT1240643 B IT 1240643B
Authority
IT
Italy
Prior art keywords
peptides containing
chain
triptofane
alchyl
peptides
Prior art date
Application number
IT20273A
Other languages
English (en)
Other versions
IT9020273A0 (it
IT9020273A1 (it
Inventor
Romano Deghenghi
Original Assignee
Mediolanum Farmaceutici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici Spa filed Critical Mediolanum Farmaceutici Spa
Publication of IT9020273A0 publication Critical patent/IT9020273A0/it
Priority to IT20273A priority Critical patent/IT1240643B/it
Priority to AU76997/91A priority patent/AU657475B2/en
Priority to DK91920995.7T priority patent/DK0531461T3/da
Priority to CA002081450A priority patent/CA2081450C/en
Priority to ES91920995T priority patent/ES2067256T3/es
Priority to EP91920995A priority patent/EP0531461B1/en
Priority to DE69105270T priority patent/DE69105270T2/de
Priority to JP50792291A priority patent/JP3319595B2/ja
Priority to PCT/EP1991/000727 priority patent/WO1991018016A1/en
Priority to AT91920995T priority patent/ATE114321T1/de
Priority to KR1019920702659A priority patent/KR100216386B1/ko
Priority to HK98105280A priority patent/HK1006173A1/en
Publication of IT9020273A1 publication Critical patent/IT9020273A1/it
Priority to US08/016,862 priority patent/US5668254A/en
Application granted granted Critical
Publication of IT1240643B publication Critical patent/IT1240643B/it
Priority to GR950400366T priority patent/GR3015146T3/el
Priority to US08/550,046 priority patent/US5635379A/en
Priority to US08/627,282 priority patent/US5646301A/en
Priority to US08/871,418 priority patent/US5872100A/en
Priority to US08/971,032 priority patent/US5955421A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT20273A 1990-05-11 1990-05-11 Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano IT1240643B (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT20273A IT1240643B (it) 1990-05-11 1990-05-11 Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
PCT/EP1991/000727 WO1991018016A1 (en) 1990-05-11 1991-04-17 Biologically active peptides containing d-2-alkyltryptophan
KR1019920702659A KR100216386B1 (ko) 1990-05-11 1991-04-17 D-2-알킬트립토판을 함유하는 생물학적 활성 펩티드
CA002081450A CA2081450C (en) 1990-05-11 1991-04-17 Biologically active peptides containing d-2-alkyltrypthophan
ES91920995T ES2067256T3 (es) 1990-05-11 1991-04-17 Peptidos biologicamente activos que contienen d-2-alquiltriptofano.
EP91920995A EP0531461B1 (en) 1990-05-11 1991-04-17 Biologically active peptides containing d-2-alkyltryptophan
DE69105270T DE69105270T2 (de) 1990-05-11 1991-04-17 D-2-alkyltryptophan enthaltende biologisch aktive peptide.
JP50792291A JP3319595B2 (ja) 1990-05-11 1991-04-17 Ｄ―２―アルキルトリプトファンを含む生物活性ペプチド
AU76997/91A AU657475B2 (en) 1990-05-11 1991-04-17 Biologically active peptides containing D-2-alkyltryptophan
AT91920995T ATE114321T1 (de) 1990-05-11 1991-04-17 D-2-alkyltryptophan enthaltende biologisch aktive peptide.
DK91920995.7T DK0531461T3 (da) 1990-05-11 1991-04-17 Biologisk aktive peptider indeholdende D-2-alkyltryptophan
HK98105280A HK1006173A1 (en) 1990-05-11 1991-04-17 Biologically active peptides containing d-2-alkyltryptophan
US08/016,862 US5668254A (en) 1990-05-11 1993-02-10 D-2-alkyl-tryptophan and peptides containing same
GR950400366T GR3015146T3 (en) 1990-05-11 1995-02-22 Biologically active peptides containing d-2-alkyltryptophan.
US08/550,046 US5635379A (en) 1990-05-11 1995-10-30 D-2-alkyl-tryptophan and peptides containing same
US08/627,282 US5646301A (en) 1990-05-11 1996-04-04 D-2-alkyl tryptophan compounds
US08/871,418 US5872100A (en) 1990-05-11 1997-06-09 Peptides containing D-2-Alkyl-Tryptophan
US08/971,032 US5955421A (en) 1990-05-11 1997-11-14 Peptides containing D-2-alkyl-Tryptophan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20273A IT1240643B (it) 1990-05-11 1990-05-11 Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano

Publications (3)

Publication Number Publication Date
IT9020273A0 IT9020273A0 (it) 1990-05-11
IT9020273A1 IT9020273A1 (it) 1991-11-11
IT1240643B true IT1240643B (it) 1993-12-17

Family

ID=11165335

Family Applications (1)

Application Number Title Priority Date Filing Date
IT20273A IT1240643B (it) 1990-05-11 1990-05-11 Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano

Country Status (13)

Country Link
EP (1) EP0531461B1 (it)
JP (1) JP3319595B2 (it)
KR (1) KR100216386B1 (it)
AT (1) ATE114321T1 (it)
AU (1) AU657475B2 (it)
CA (1) CA2081450C (it)
DE (1) DE69105270T2 (it)
DK (1) DK0531461T3 (it)
ES (1) ES2067256T3 (it)
GR (1) GR3015146T3 (it)
HK (1) HK1006173A1 (it)
IT (1) IT1240643B (it)
WO (1) WO1991018016A1 (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872100A (en) * 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
EP1082959A1 (en) 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
AU6010394A (en) * 1993-02-23 1994-09-14 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonist
DE69528531T2 (de) * 1994-09-27 2003-06-05 Ardana Bioscience Ltd., Edinburgh D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
IT1277113B1 (it) * 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
CA2290592A1 (en) 1997-05-13 1998-11-19 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for decreasing body weight
EP0981364B1 (en) 1997-05-13 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Method and compositions for treating hyperlipidemia
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
JP4116097B2 (ja) 1997-06-20 2008-07-09 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性をもつ化合物
ATE470671T1 (de) 1998-01-16 2010-06-15 Helsinn Therapeutics Us Inc Verbindungen mit wachstumshormon-freisetzender eigenschaft
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
NZ530007A (en) 2001-06-08 2006-02-24 Sod Conseils Rech Applic Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CA2523197C (en) 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
BRPI0515372B8 (pt) 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2310028B1 (en) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
CN121127483A (zh) * 2023-05-18 2025-12-12 港大科桥有限公司 对天然肽色氨酸残基的精确后期修饰

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080470A (en) * 1963-12-31 1967-08-23 Merck & Co Inc Indole derivatives
WO1983002272A1 (en) * 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides

Also Published As

Publication number Publication date
KR100216386B1 (ko) 1999-08-16
WO1991018016A1 (en) 1991-11-28
AU657475B2 (en) 1995-03-16
JPH05507066A (ja) 1993-10-14
IT9020273A0 (it) 1990-05-11
EP0531461A1 (en) 1993-03-17
CA2081450C (en) 2001-03-27
ES2067256T3 (es) 1995-03-16
IT9020273A1 (it) 1991-11-11
AU7699791A (en) 1991-12-10
EP0531461B1 (en) 1994-11-23
DE69105270D1 (de) 1995-01-05
JP3319595B2 (ja) 2002-09-03
ATE114321T1 (de) 1994-12-15
DK0531461T3 (da) 1995-05-15
CA2081450A1 (en) 1991-11-12
GR3015146T3 (en) 1995-05-31
DE69105270T2 (de) 1995-04-13
HK1006173A1 (en) 1999-02-12

Similar Documents

Publication Publication Date Title
DK0531461T3 (da) Biologisk aktive peptider indeholdende D-2-alkyltryptophan
NZ503720A (en) Nucleotide sequences encoding ApoA-I agonists and their use in pharmaceutical compositions to treat dyslipidemic disorders such as cardiovascular disease
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
FI962350A0 (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
PT987998E (pt) Descelularizacao de tecidos
IT9067125A0 (it) Protesi valvolare cardiaca
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
EP1156820A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR-2
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
FR2662698B1 (it)
DE69633133D1 (de) TFPI-verwandte Peptide die das Wachstums von glatten Muskelzellen inhibieren
NZ230654A (en) Anti-cell proliferative penta and hexa peptides
CS395890A3 (en) Pharmaceutical for treating cardial and vascular hypertropia andhyperplasia
ATE216881T1 (de) Zusammensetzung auf basis von enalapril und losartan
ATE135873T1 (de) Schaltungsanordnung zum impulsbetrieb von hochdruckentladungslampen
FI883247A0 (fi) 7-/1h-pyrrool-3-yl/-substituerade 3,5-dihydroxihept-6-ensyror, 7-/1h-pyrrol-3-yl/-susbtituerade 3,5 -dihydroxiheptansyror, motsvarande -laktoner och salter av dem, foerfarande foer framstaellning av dessa, deras anvaendning som laekemedel, farmaceutiska preparat och mellanprodukter.
ES2163717T3 (es) Derivados de pirrolidinona y su uso como medicamentos antipsicoticos.
ES2131339T3 (es) Peptidos para tratamiento antialergico.
IT1264129B1 (it) Peptidi ad attivita' immunomodulatoria derivati da frammenti di leucochinina
Tsaregorodtsev Practical aspects of establishment of joint venture companies
IT1243778B (it) Derivati salini dell'acido tauroursodesossicolico, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970530